Reproductive Health

Hormone Testing Company Proov Announces Third Patent to Identify the Fertile Window Using LH and PdG Tests

Proov, a science-based hormone testing company, has received patent issue notification for its third utility patent, protecting the use of a LH test to identify the opening of the fertile window and the later use of a separate PdG test to identify the closing of the fertile window. The patented method protects uses associated with Proov’s soon to be announced app platform,…

Berlin-based Keleya Raises a €3M Series A to Continue Growing its Platform for Parents-to-Be

Berlin-based Keleya has recently announced a €3M Series A to expand and continue growing both its signature app for parents-to-be and its sister site Ammely, a midwife matching platform. Participating investors in this recent round include Crista-Galli Ventures, Calm/Storm Ventures and SeedLink SL. “Lack of access to midwives isn’t a new phemomenon, that started during the pandemic. Around 30% of parents-to-be in…

Next Health Accelerator, a New Senegalese Program Addressing Sexual and Reproductive Health in Africa, Announces its First Cohort

Intrepid Entrepreneurs has recently announced the 9 selected startups that represent the inaugural cohort of the Next Health Accelerator, that aims to support African, female entrepreneurs disrupting the sexual and reproductive health. The 9 startups chosen represent 7 countries: The DRC, The Gambia, Ghana, Kenya, Nigeria, Rwanda, and Uganda.  Next Health Accelerator is a 6-month program to catalyze startups for investor readiness and value chain access. The program’s focus is on sexual and reproductive health and self-care and is…

Fertility Startup kegg Raises $1.5M to Invest in B2B Growth

Lady Technologies, the company behind kegg, has announced a $1.5M seed II round to invest in B2B growth. This brings the company’s total funding to $3M. This latest round was led by Crescent Ridge Partners Allison Long-Pettine and Maria Gonzalez-Blanch. Other participants include SOSV, Texas Halo Fund, Althea Capital Fund, Ad Astra Ventures, Viento Ventures, fermata, and the Intent Impact Fund. Lady…

Bayer’s Mirena IUD Gets FDA Approval for Pregnancy Prevention for Up to 7 Years

Bayer has announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) that extends the duration of use for its intrauterine device (IUD) Mirena (levonorgestrel-releasing intrauterine system) 52 mg by one year, making it available to prevent pregnancy for up to seven years. The approval is based on results from a Phase 3 extension trial evaluating the…

Dove Introduces a Black Birth Equity Fund to Help Close the Maternal Care Gap

Black women are 3-4x more likely to die of pregnancy related causes than white women, yet more than 60% of pregnancy related death could have been prevented. Black babies are two times more likely to die a premature death compared to white babies. Today, the US has one of the highest rates of maternal mortality in the developing world. Black women are…

Visby Medical Receives FDA Clearance and CLIA Waiver at the Point of Care for Click Test, its PCR Sexual Health Test

Visby Medical has received a 510(k) clearance and was granted a waiver under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) from the US Food and Drug Administration (FDA) to market its fast, single-use polymerase chain reaction (PCR) diagnostic test for the multiplexed detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Trichomonas vaginalis (TV), using a self-collected vaginal swab.  With the…

TherapeuticsMD Receives a J-Code for its Long-Lasting, Patient-Controlled Contraceptive ANNOVERA

Women’s Healthcare company TherapeuticsMD has announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA. According to TherapeuticsMD, ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is the first and only FDA-approved long-lasting, reversible contraceptive for women of reproductive age that is patient-controlled…